NEW YORK , March 23, 2021 (GLOBE NEWSWIRE) -- Cipla Therapeutics, a division of Cipla USA Inc. , an affiliate of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; referred to as "Cipla") and SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health

-  Approximately 363,000 Courses of Oral TPOXX® Delivered to U.S. Government in 2020 – - International Contracts for the Purchase of up to Approximately $47 Million of Oral TPOXX® Since April 2020   – - Corporate Update Conference Call Today at 4:30 PM ET   - NEW YORK , March 04, 2021 (GLOBE

NEW YORK , Feb. 26, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M.

Second Contract by a Canadian Governmental Agency for the Procurement of Oral TPOXX NEW YORK , Jan. 13, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Public Health